Skip to main content

Table 1 Cohorts and dose levels

From: A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma

Cohort

A

B

C

D

Incremental percent

Starting dose

20%

17%

14%

Dose level

2700 mg/day

(1350 mg BID)

3240 mg/day

(1620 mg BID)

3780 mg/day

(1890 mg BID)

4320 mg/day

(2160 mg BID)

Number of patient

3

3

3

3